Pharma company Venus Remedies Ltd today said it has filed its fifth International Patent application for its latest antibiotic fixed dose combination used in the treatment of Cystis Fibrosis.
The new antibiotic combination, active against multi-resistant strains of both gram- positive and gram-negative bacteria and provides a broad-spectrum coverage of bactericidal activity, it informed the Bombay Stock Exchange.
Respiratory Diseases - Cystic Fibrosis
Encyclopedia section of medindia gives general info about Cystic Fibrosis
Advertisement
The fixed dose combination was developed by company's R&D centre and it had filed the Indian patent for this product, titled "Treatment and Control of severe infections, including Cystis Fibrosis", in May 2005, it said.
Cystis Fibrosis is a common hereditary disease that affects the entire body, causing progressive disability and early death.
The global market for the antibiotic is worth 500 million dollar, it added.
Source:PTI News
The global market for the antibiotic is worth 500 million dollar, it added.
Source:PTI News
Advertisement
Advertisement
|
Advertisement
Latest Drug News
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
Women using hormonal contraception, along with their healthcare providers, should explore alternative pain relief options instead of NSAIDs.
The recently created assay identifies antipsychotic drugs present in sweat.
